Cargando…
597. Comparison of Vancomycin and Daptomycin Complications and Interventions in Outpatient Parenteral Antimicrobial Therapy
BACKGROUND: Vancomycin and daptomycin are commonly used in outpatient parenteral antimicrobial therapy (OPAT) for patients requiring lengthy courses of intravenous antimicrobials who are otherwise stable for discharge. Balancing the convenience and cost-savings of OPAT with the potential for adverse...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7777184/ http://dx.doi.org/10.1093/ofid/ofaa439.791 |
_version_ | 1783630844355674112 |
---|---|
author | Nakrani, Monark Yu, Diana Sikka, Monica Lewis, James Douglass, Alyse Mayer, Heather Young, Kathleen Streifel, Amber C |
author_facet | Nakrani, Monark Yu, Diana Sikka, Monica Lewis, James Douglass, Alyse Mayer, Heather Young, Kathleen Streifel, Amber C |
author_sort | Nakrani, Monark |
collection | PubMed |
description | BACKGROUND: Vancomycin and daptomycin are commonly used in outpatient parenteral antimicrobial therapy (OPAT) for patients requiring lengthy courses of intravenous antimicrobials who are otherwise stable for discharge. Balancing the convenience and cost-savings of OPAT with the potential for adverse effects is challenging, this study compared the rates of complications and antimicrobial interventions for patients receiving vancomycin versus daptomycin across multiple OPAT settings. METHODS: We performed a retrospective chart review of adult OPAT patients who received >72 hours of vancomycin or daptomycin via home infusion, infusion center, or skilled nursing facility between January 2017 and August 2019. The outcomes evaluated included the rates of adverse drug reactions (ADRs), laboratory results above a defined threshold (vancomycin levels >20 mg/mL in the vancomycin arm and creatinine phosphokinase (CPK) levels >500 units/L in the daptomycin group), line complications, emergency department (ED) visits, and hospital readmissions. Other outcomes included additional phone calls and interventions required to coordinate care (additional labs, assessment of symptoms, additional test or antimicrobial-related dose changes) by the OPAT team. RESULTS: 180 patients were included; 130 received vancomycin and 50 received daptomycin. (Table 1) Patients in the vancomycin group had more supratherapeutic vancomycin troughs than elevated CPK for patients in the daptomycin group (rate ratio [RR] 0.16, 95% CI 0.05-0.50, p=0.0018). Rates of interventions (RR 0.37, 95% CI 0.26-0.52, p< 0.0001) and additional phone calls (RR 0.56, 95% CI 0.43-0.72, p< 0.0001) were also higher for patients in the vancomycin group. There were no statistically significant differences between groups in the rates of ADRs, line complications, ED visits, or hospital readmissions. (Table 2) Table 1. Baseline Characteristics [Image: see text] Table 2. Outcomes [Image: see text] CONCLUSION: Vancomycin-treated patients had significantly more laboratory abnormalities and required significantly more time in patient care coordination by the OPAT team. The difference in healthcare utilization between these groups suggests a potential for significant cost-savings for OPAT patients and the healthcare system. DISCLOSURES: All Authors: No reported disclosures |
format | Online Article Text |
id | pubmed-7777184 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-77771842021-01-07 597. Comparison of Vancomycin and Daptomycin Complications and Interventions in Outpatient Parenteral Antimicrobial Therapy Nakrani, Monark Yu, Diana Sikka, Monica Lewis, James Douglass, Alyse Mayer, Heather Young, Kathleen Streifel, Amber C Open Forum Infect Dis Poster Abstracts BACKGROUND: Vancomycin and daptomycin are commonly used in outpatient parenteral antimicrobial therapy (OPAT) for patients requiring lengthy courses of intravenous antimicrobials who are otherwise stable for discharge. Balancing the convenience and cost-savings of OPAT with the potential for adverse effects is challenging, this study compared the rates of complications and antimicrobial interventions for patients receiving vancomycin versus daptomycin across multiple OPAT settings. METHODS: We performed a retrospective chart review of adult OPAT patients who received >72 hours of vancomycin or daptomycin via home infusion, infusion center, or skilled nursing facility between January 2017 and August 2019. The outcomes evaluated included the rates of adverse drug reactions (ADRs), laboratory results above a defined threshold (vancomycin levels >20 mg/mL in the vancomycin arm and creatinine phosphokinase (CPK) levels >500 units/L in the daptomycin group), line complications, emergency department (ED) visits, and hospital readmissions. Other outcomes included additional phone calls and interventions required to coordinate care (additional labs, assessment of symptoms, additional test or antimicrobial-related dose changes) by the OPAT team. RESULTS: 180 patients were included; 130 received vancomycin and 50 received daptomycin. (Table 1) Patients in the vancomycin group had more supratherapeutic vancomycin troughs than elevated CPK for patients in the daptomycin group (rate ratio [RR] 0.16, 95% CI 0.05-0.50, p=0.0018). Rates of interventions (RR 0.37, 95% CI 0.26-0.52, p< 0.0001) and additional phone calls (RR 0.56, 95% CI 0.43-0.72, p< 0.0001) were also higher for patients in the vancomycin group. There were no statistically significant differences between groups in the rates of ADRs, line complications, ED visits, or hospital readmissions. (Table 2) Table 1. Baseline Characteristics [Image: see text] Table 2. Outcomes [Image: see text] CONCLUSION: Vancomycin-treated patients had significantly more laboratory abnormalities and required significantly more time in patient care coordination by the OPAT team. The difference in healthcare utilization between these groups suggests a potential for significant cost-savings for OPAT patients and the healthcare system. DISCLOSURES: All Authors: No reported disclosures Oxford University Press 2020-12-31 /pmc/articles/PMC7777184/ http://dx.doi.org/10.1093/ofid/ofaa439.791 Text en © The Author 2020. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Poster Abstracts Nakrani, Monark Yu, Diana Sikka, Monica Lewis, James Douglass, Alyse Mayer, Heather Young, Kathleen Streifel, Amber C 597. Comparison of Vancomycin and Daptomycin Complications and Interventions in Outpatient Parenteral Antimicrobial Therapy |
title | 597. Comparison of Vancomycin and Daptomycin Complications and Interventions in Outpatient Parenteral Antimicrobial Therapy |
title_full | 597. Comparison of Vancomycin and Daptomycin Complications and Interventions in Outpatient Parenteral Antimicrobial Therapy |
title_fullStr | 597. Comparison of Vancomycin and Daptomycin Complications and Interventions in Outpatient Parenteral Antimicrobial Therapy |
title_full_unstemmed | 597. Comparison of Vancomycin and Daptomycin Complications and Interventions in Outpatient Parenteral Antimicrobial Therapy |
title_short | 597. Comparison of Vancomycin and Daptomycin Complications and Interventions in Outpatient Parenteral Antimicrobial Therapy |
title_sort | 597. comparison of vancomycin and daptomycin complications and interventions in outpatient parenteral antimicrobial therapy |
topic | Poster Abstracts |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7777184/ http://dx.doi.org/10.1093/ofid/ofaa439.791 |
work_keys_str_mv | AT nakranimonark 597comparisonofvancomycinanddaptomycincomplicationsandinterventionsinoutpatientparenteralantimicrobialtherapy AT yudiana 597comparisonofvancomycinanddaptomycincomplicationsandinterventionsinoutpatientparenteralantimicrobialtherapy AT sikkamonica 597comparisonofvancomycinanddaptomycincomplicationsandinterventionsinoutpatientparenteralantimicrobialtherapy AT lewisjames 597comparisonofvancomycinanddaptomycincomplicationsandinterventionsinoutpatientparenteralantimicrobialtherapy AT douglassalyse 597comparisonofvancomycinanddaptomycincomplicationsandinterventionsinoutpatientparenteralantimicrobialtherapy AT mayerheather 597comparisonofvancomycinanddaptomycincomplicationsandinterventionsinoutpatientparenteralantimicrobialtherapy AT youngkathleen 597comparisonofvancomycinanddaptomycincomplicationsandinterventionsinoutpatientparenteralantimicrobialtherapy AT streifelamberc 597comparisonofvancomycinanddaptomycincomplicationsandinterventionsinoutpatientparenteralantimicrobialtherapy |